4-氯噻吩并[3,2-d]嘧啶 | 16269-66-2

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 中文名称: 4-氯噻吩并[3,2-d]嘧啶
• 中文别名: 4-氯噻酚并[3,2-D]嘧啶；4-氯噻吩并[3,2-D]嘧啶；4-氯噻酚[3,2-D]嘧啶
• 英文名称: 4-chlorothieno[3,2-d]pyrimidine
• 英文别名: 4-chlorothieno[3, 2-b]pyrimidine
• CAS: 16269-66-2
• 化学式: C₆H₃ClN₂S
• mdl: MFCD00122144
• 分子量: 170.622
• InChiKey: TWTODSLDHCDLDR-UHFFFAOYSA-N

物化性质

• 熔点：
  125 °C
• 沸点：
  285.7±20.0 °C(Predicted)
• 密度：
  1.531±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S26,S37/39
• 危险类别码：
  R22,R36/37/38
• 海关编码：
  2934999090
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C

SDS

Name:	4-Chlorothieno[3 2-d]pyrimidine 97% Material Safety Data Sheet
Synonym:
CAS:	16269-66-2

Section 1 - Chemical Product MSDS Name:4-Chlorothieno[3 2-d]pyrimidine 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
16269-66-2	4-Chlorothieno[3,2-d]pyrimidine	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 16269-66-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: light brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 124 - 126 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H3ClN2S
Molecular Weight: 171

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 16269-66-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Chlorothieno[3,2-d]pyrimidine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 16269-66-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 16269-66-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 16269-66-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氯噻吩并[3,2-d]嘧啶 在 ammonium hydroxide 作用下， 以 乙醇 为溶剂， 反应 8.0h， 以81.4%的产率得到4-氨基噻吩并[3,2-D]嘧啶
  参考文献：
  名称：

  新型KDR激酶抑制剂1-（4-氯-3-（三氟甲基）-苯基）-3-（2-（氨基）吡啶-3-基）脲的发现和优化

  摘要：

  激酶插入物含域受体（KDR）是抗癌药物发现和开发的当前验证目标之一。在此，已经合成了一系列邻氨基-芳基脲衍生物，并评估了它们的激酶抑制活性。在生物学筛选和分子建模的基础上进行优化，与该命中化合物相比，可明显提高KDR激酶的抑制活性。最终，我们确定了针对KDR的1-（4-氯-3-（三氟甲基）苯基）-3-（2-（（喹啉-4-基甲基）氨基）吡啶-3-基）脲支架的有效抑制剂5a（ IC 50 = 0.0689 µM），可以作为进一步优化KDR抑制剂和开发的良好起点。

  DOI：

  10.2174/1573406412666151215105149
• 作为产物：
  描述：

  噻吩并[3,2-d]嘧啶,4-(甲硫基)- 在 磺酰氯 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 0.5h， 以99%的产率得到4-氯噻吩并[3,2-d]嘧啶
  参考文献：
  名称：

  用硫酰氯对嘧啶环系统上的甲基硫烷基进行有效的一步氯化

  摘要：

  使用乙腈/二氯甲烷中的硫酰氯，可轻松实现嘧啶环系统上甲基硫烷基和芳基硫烷基的一步式转化为相应的氯基。

  DOI：

  10.1016/j.tetlet.2010.06.056
• 作为试剂：
  描述：

  5-(2-氨基乙基)噻唑-2-氨基甲酸叔丁酯 、 4-氯噻吩并[3,2-d]嘧啶 在 4-氯噻吩并[3,2-d]嘧啶 作用下， 以75的产率得到{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)-ethyl]-thiazol-2-yl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Thienopyrimidines useful as Aurora kinase inhibitors

  摘要：

  本发明提供具有以下式子的化合物：其中R1，R2，X1，X2，L1，L2，Y和Z如本类和子类中所定义，并且其药物组成物，如本类和子类中所描述，这些化合物可用作蛋白激酶（例如Aurora）的抑制剂，因此可用于治疗Aurora介导的疾病。

  公开号：

  US07601725B2

文献信息

• ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT
  申请人：Centre National de la Recherche Scientifique

  公开号：US20210009581A1

  公开（公告）日：2021-01-14

  The present invention concerns a compound of following general formula (I): where: either R is an R 1 group and R′ is an -A 1 -Cy 1 group, or R is an -A 1 -Cy 1 group and R′ is an R 1 group, R 1 particularly being H or (C 1 -C 6 )alkyl group; A 1 being an —NH— radical or —NH—CH 2 — radical; Cy 1 particularly being a phenyl group, A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.

  本发明涉及以下一般式（I）的化合物： 其中： R是R1基团且R′是-A1-Cy1基团，或者R是-A1-Cy1基团且R′是R1基团， 其中R1特别是H或（C1-C6）烷基基团； A1是—NH—基团或—NH—CH2—基团； Cy1特别是苯基， A是具有5到7个原子的融合（杂）芳香环， 用于治疗癌症。
• Bicyclic compounds capable of inhibiting tyrosine kinases of the
  申请人：Warner-Lambert Company

  公开号：US05654307A1

  公开（公告）日：1997-08-05

  Novel 4-substituted amino pyrido pyrimidine and 4-substituted amino pyrido pyrimidine inhibitors of epidermal growth factor receptor family of tyrosine kinase are described, as well as pharmaceutical compositions of the same, which are useful in treating proliferative diseases such as cancer, synovial pannus invasion in arthritis, psoriasis, vascular restenosis and angiogenesis and additionally useful in the treatment of pancreatitis and kidney disease as well as a contraceptive agent.

  描述了新型4-取代氨基吡啶嘧啶和4-取代氨基吡啶嘧啶抑制剂对表皮生长因子受体家族的酪氨酸激酶的作用，以及相应的药物组合物，这些药物在治疗癌症、关节炎中的滑膜侵袭、牛皮癣、血管再狭窄和血管生成方面非常有用，此外还可用于治疗胰腺炎和肾病，以及作为避孕药剂。
• THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS
  申请人：Gopalsamy Ariamala

  公开号：US20090118276A1

  公开（公告）日：2009-05-07

  The present invention relates to compounds of formula la: and pharmaceutically acceptable salts thereof. The thieno[3,2-d]pyrimidine, thieno[2,3-d]pyrimidine, thieno[3,2-b]pyridine, thieno[2,3-b]pyridine, and pyrrolo[2,3-d]pyrimidine compounds selectively inhibit B-Raf kinase activity and are useful for treating disorders mediated by B-Raf kinase, and for the treatment of cancer.

  本发明涉及下式(Ia)的化合物： 以及药用可接受的盐。这些噻吩[3,2-d]嘧啶、噻吩[2,3-d]嘧啶、噻吩[3,2-b]吡啶、噻吩[2,3-b]吡啶和吡咯[2,3-d]嘧啶化合物选择性地抑制B-Raf激酶活性，并可用于治疗由B-Raf激酶介导的疾病，以及用于治疗癌症。
• [EN] ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS<br/>[FR] DÉRIVÉS D'ISOCHROMÈNE UTILES EN TANT QU'INHIBITEURS DES PHOSPHOINOSITIDE 3-KINASES
  申请人：CHIESI FARMA SPA

  公开号：WO2015091685A1

  公开（公告）日：2015-06-25

  The invention relates to compounds inhibiting phosphoinositide 3-kinases (PI3K), to pharmaceutical compositions comprising them and therapeutic use thereofin the treatment of disorders associated with PI3K enzymes.

  本发明涉及抑制磷脂酰肌醇3-激酶（PI3K）的化合物，包括含有它们的药物组合物以及它们在治疗与PI3K酶相关疾病的用途。
• ISOCHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS
  申请人：CHIESI FARMACEUTICI S.p.A.

  公开号：US20150166549A1

  公开（公告）日：2015-06-18

  Compounds of formula (I) described herein are useful for inhibiting phosphoinositide 3-kinases (PI3K) and the treatment of disorders associated with PI3K enzymes.

  根据此处描述的公式(I)的化合物对于抑制磷脂酰肌醇3-激酶（PI3K）以及治疗与PI3K酶相关联的疾病是有用的。